Rigel Pharmaceuticals (RIGL) Competitors

Dynavax Technologies (NASDAQ:DVAX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings.

Which has more risk & volatility, DVAX or RIGL?

Dynavax Technologies has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Does the MarketBeat Community believe in DVAX or RIGL?

Dynavax Technologies received 10 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. However, 68.88% of users gave Rigel Pharmaceuticals an outperform vote while only 65.79% of users gave Dynavax Technologies an outperform vote.

Company	Underperform	Outperform
Dynavax Technologies	Outperform Votes 477 65.79%	Underperform Votes 248 34.21%
Rigel Pharmaceuticals	Outperform Votes 467 68.88%	Underperform Votes 211 31.12%

Which has stronger earnings & valuation, DVAX or RIGL?

Dynavax Technologies has higher revenue and earnings than Rigel Pharmaceuticals. Dynavax Technologies is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynavax Technologies	$294.62M	4.16	-$6.39M	-$0.52	-19.64
Rigel Pharmaceuticals	$203.08M	1.77	-$25.09M	$2.07	9.69

Do institutionals & insiders hold more shares of DVAX or RIGL?

97.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 3.0% of Dynavax Technologies shares are held by insiders. Comparatively, 9.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is DVAX or RIGL more profitable?

Dynavax Technologies has a net margin of 9.85% compared to Rigel Pharmaceuticals' net margin of 2.46%. Dynavax Technologies' return on equity of 4.22% beat Rigel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dynavax Technologies	9.85%	4.22%	2.67%
Rigel Pharmaceuticals	2.46%	-14.80%	3.03%

Do analysts rate DVAX or RIGL?

Dynavax Technologies currently has a consensus target price of $24.00, indicating a potential upside of 134.95%. Rigel Pharmaceuticals has a consensus target price of $36.40, indicating a potential upside of 81.46%. Given Dynavax Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Dynavax Technologies is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynavax Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Does the media prefer DVAX or RIGL?

In the previous week, Dynavax Technologies had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 6 mentions for Dynavax Technologies and 5 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.54 beat Dynavax Technologies' score of 1.31 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dynavax Technologies	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Dynavax Technologies beats Rigel Pharmaceuticals on 11 of the 18 factors compared between the two stocks.